{
    "organizations": [],
    "uuid": "5c7ca9e1d9837926f7d42b9befe75ec918d909ed",
    "author": "",
    "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-says-zyn00/brief-zynerba-pharmaceuticals-says-zyn002-was-shown-to-be-well-tolerated-through-12-months-of-treatment-in-star-2-study-idUSFWN1S20R0",
    "ord_in_thread": 0,
    "title": "BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Zynerba Pharmaceuticals Inc:\n* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2\n* ZYNERBA PHARMACEUTICALS - LOOK FORWARD TO INITIATING A PHASE 2B STUDY IN ADULT REFRACTORY FOCAL SEIZURES IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T14:15:00.000+03:00",
    "crawled": "2018-04-25T14:30:49.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "zynerba",
        "pharmaceutical",
        "inc",
        "zynerba",
        "pharmaceutical",
        "say",
        "zyn002",
        "shown",
        "well",
        "tolerated",
        "month",
        "treatment",
        "star",
        "zynerba",
        "pharmaceutical",
        "look",
        "forward",
        "initiating",
        "phase",
        "2b",
        "study",
        "adult",
        "refractory",
        "focal",
        "seizure",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}